Objective: To determine the minimum effective dose of folic acid required to appreciably increase serum folate and to produce a significant reduction in plasma total homocysteine (tHcy). Design: Double-blind, randomised placebo-controlled intervention trial. Setting: Community-based project in a New Zealand city. Subjects: Seventy free living men and women with tHcy ! 10 mmol=l. Mean age (range) was 58 (29 -90) y. Interventions: Daily consumption over 4 weeks of 20 g breakfast cereal either unfortified (placebo) or fortified with 100, 200 or 300 mg folic acid. Dietary intake was determined by weighed diet records and consumption of commercially fortified products was avoided. Main outcome measures: Plasma tHcy and serum folate concentrations. Results: Average serum folate concentrations (95% CI) increased significantly in the treatment groups relative to the control group by 28(9 -51)%, 60(37 -87)% and 79(51 -114)% for supplementation with 100, 200 and 300 mg folic acid, respectively. A reduction in tHcy was observed, being 16(8 -22)%, 12(4 -18)% and 17(9 -24)% in the three treatment groups, respectively. Conclusions: A regular intake of as little as 100 mg folic acid per day was sufficient to lower tHcy in persons at the upper end of the normal range for tHcy. Low-level fortification may also be appropriate for lowering the risk of neural tube defects given that, when aggregated from all sources, the total intake of folic acid may be sufficiently high to adequately improve the folate status of young women. Funding: The breakfast cereals were supplied and the study partially funded by Kellogg Company.
Introduction
Mandatory fortification of enriched grain products with folic acid was introduced in the United States in 1998 as a means of increasing the folate intake of young women to reduce the incidence of neural tube defects (NTDs) in their offspring (Department of Health and Human Services, Food and Drug Administration, 1996) . Enhancing the folate status of the general population would also be expected to reduce levels of homocysteine, an amino acid considered to be a risk factor for vascular disease (Eikelboom et al, 1999) , thus providing additional justification for fortification. Fortification, either mandatory or voluntary, is practised in several countries including the UK, but there is little certainty regarding the most appropriate level of folic acid. We wished to determine the minimum effective dose required to lower plasma total homocysteine (tHcy) on the assumption that a doseresponse relationship existed between tHcy and relatively low dose supplementation with folic acid. It has previously been shown that providing 300 mg folic acid daily achieves lowering of tHcy to the same extent as appreciably higher levels of intake (Riddell et al, 2000) . Thus we elected to study levels that would provide between 100 and 300 mg folic acid per day. Breakfast cereals were chosen as the vehicle of fortification since they would provide the source of folic acid for many people under a general fortification policy. Those with tHcy levels at the upper end of the range were selected to participate in the study since they were considered likely to show the greatest reduction in tHcy from folic acid fortification. The primary hypothesis was that a doseresponse relationship existed between tHcy and folic acid within the range of 100 -300 mg folic acid received as a daily dose contained in fortified breakfast cereals. The results of this study should assist in the determination of an appropriate level of folic acid fortification required to lower tHcy.
Methods

Study population
Over the period June to September 1999, 531 residents of Dunedin, New Zealand, responded to an advertisement in a local newspaper. Participants were invited to take part if they were 18 y of age or older and had a fasting plasma tHcy ! 10 mmol=l. Respondents were not eligible if they were using anti-convulsants, fibrates or hormone replacement therapy (HRT); or were pregnant or had been diagnosed with HIV, hepatitis or pernicious anaemia. The University of Otago Human Ethics Committee approved the study. As a result of screening blood tests 143 people with tHcy levels ! 10 mmol=l were identified. Nineteen people were unable to participate because the start date of the study was delayed until February 2000. Other exclusions and withdrawals are shown in Figure 1 . Seventy participants were subsequently randomised (33 women, 37 men). One person reported using a multivitamin supplement prior to the study, the remainder had not used supplements containing folic acid.
Treatments
The control group received unfortified breakfast cereal and three groups received cereals fortified either at 100, 200 or 300 mg per serving. Figure 2 shows the sequence and timing of blood sampling and data collection. At recruitment (week -2) a registered dietitian instructed participants to follow recommendations for healthy eating (The National Heart Foundation of New Zealand, 1997). It should be noted that instruction was given before the baseline blood measurements were taken to ensure that dietary intakes remained constant throughout the study period. Participants were told to avoid eating foods fortified with folic acid and provided with a list of unfortified brands. They were supplied with electronic kitchen scales accurate to 2 g and instructed how to complete a weighed food record, the first 4 day record being completed prior to baseline, and the second towards Figure 1 Flowchard describing progress of respondents through randomised trial. *20 people were randomly assigned to another study that examined the effects of increasing folate from foods.
Low-dose fortification with folic acid BJ Venn et al the end of the intervention period. Breakfast cereals, appropriate to the treatment groups, were provided in sufficient quantity for the duration of the intervention. Participants were instructed to weigh and eat 20 g of cereal each day and given a compliance check list. Duplicate fasting blood samples, drawn 48 h apart, were collected at baseline and at the end of intervention. Lipid, lipoprotein and tHcy measurements were determined on all blood samples. Serum folate and serum vitamin B 12 were determined on one blood sample at week 0 and week 4; plasma glucose and creatinine were determined at baseline.
Outcome measures
The primary outcome measures were responses of tHcy and serum folate to three levels of folic acid intake compared with that observed in the control group. Dietary data were collected before and during intervention to assess any dietary changes that may have influenced the primary outcome variables. Group sizes were determined by power calculations based on tHcy responses in a previous study to 300 mg folic acid contained in breakfast cereals (Riddell et al, 2000) . A sample of 14 in each group had an 80% chance of detecting a 20% difference between the treatments using the 5% level of significance using log transformed data.
Randomisation
Names were written onto cards and stratified according to sex. Cards were allocated by simple randomisation into one of four coded groups. The generator was blinded as to the treatment schedule for each group. All participants were randomised at the same time to give the distribution shown in Table 1 .
Masking
The breakfast cereals were received from the manufacturer in boxes indicating the level of fortification. This information was removed and the boxes coded by a staff member not involved with the study so that neither the research team nor the participants were aware of which treatment was being allocated. The code was broken after analysis of all blood samples.
Laboratory analyses
Total folate contents of breakfast cereals were checked by microbiological assay using Lactobacillus casei with trienzyme extraction (Rader et al, 1998) , at the Department of Food Science and Technology, University of New South Wales, Australia. The laboratory was blinded as to the nominal level of fortification. For cereals nominally fortified at 100, 200 and 300 mg the reported levels were 115, 216 and 307 mg folic acid per 20 g serving size, respectively. Blood samples for tHcy, lipids, glucose and creatinine measurements were Low-dose fortification with folic acid BJ Venn et al collected in EDTA tubes, placed on ice immediately, separated within 2 h by centrifugation (2000 g for 10 min at 4 C) and plasma was stored at 7 20 C prior to analysis. Serum folate and vitamin B 12 was measured by a chemiluminescence method ACS180 1 (Ciba Corning E, Walpole, MA, USA), coefficients of variation (CV) 10.9 and 4.3%, respectively. Plasma tHcy was determined using HPLC with fluorescence detection by adaptation of the method of Ubbink et al (1991) using cystamine dihydrochloride as an internal standard (Loehrer et al, 1996) . One pool sample was inserted for every 10 samples, (the CV within batches was 6.7% and between batches 6.9%). The four samples from each subject (two baseline, two after intervention) were analysed in a single run to eliminate between-run variation. Total cholesterol concentration in plasma and lipoprotein fractions was measured enzymatically with Boehringer kits and calibrators on a Cobas Fara analyser (CV 0.9%). Plasma glucose and creatinine were measured enzymatically using Roche diagnostic kits on a Cobas Fara analyser (CV 1.1 and 4.5%, respectively).
Identification of the 677C?T polymorphism in the gene encoding for 5,10-methylenetetrahydrofolate reductase (MTHFR) was conducted after extraction of DNA from blood samples by adaptation of published methods (Jeanpierre, 1987; Bowtell, 1987) . The upstream primer, 5 0 AGG-GAGCTTTGAGGCTGACCTGAA, and downstream primer, 5 0 GGGGACGATGGGGCAAGTGAT, were designed to amplify a 151 base pair (bp) fragment bracketing the polymorphism. Polymerase chain reaction was performed with final concentrations of 10 ng=ml DNA, 0.2 mM dNTP, 250 nM each primer, 1Âbuffer (Qiagen, Hilden, Germany) and 0.025 U=ml Taq (Qiagen) in a 20 ml reaction. The thermal cycler (Hybaid PCR Express, Middlesex, UK) was set to denature for 3 min at 94 C, followed by 35 cycles of 94 C for 30 s, 62 C for 30 s and 72 C for 20 s with a final 2 min extension at 72 C. HinfI (New England Biolabs) was diluted to 0.66 U=ml as per the manufacturer's instructions and 2 U were added to each sample reaction. The plate was incubated at 37 C for 120 min to ensure complete digestion of the T allele into 101 and 50 bp fragments, the C allele was unaltered. Samples were electrophoresed on an agarose gel, stained with ethidium bromide and viewed under ultraviolet light. Two independent observers classified each sample into one of three genotypes, CC, CT and TT.
Dietary analysis
The USDA food composition database was used to provide the methionine content of foods (USDA Nutrient database for standard reference, release 13). All other nutrient values were based on NZ food composition data (Food Files, 1993) and the diet records analysed using 'Diet Cruncher' software (Marshall, 1993) .
Statistical analysis
Where appropriate, data were log transformed to normalise the distribution and back-transformed to geometric means with 95% confidence intervals (CI). Multiple regression was used to estimate the difference between the control and each treatment group after adjusting for baseline values, differences being expressed as ratios. Comparison between the two 4-day diet records was made after log transformation with a paired t-test. The analyses were undertaken using SPSS for Windows release 6.1.3 (SPSS Inc.). All analyses were carried out on an intention to treat basis. Low-dose fortification with folic acid BJ Venn et al
Results
The baseline characteristics of the control and three treatment groups are presented in Table 1 . Baseline average tHcy concentrations for the CC, CT and TT genotypes were 13.8, 13.4 and 13.5 mmol=l, respectively. The results of the intervention are shown in Table 2 and presented as ratios (95% CI) relative to the control group. With reference to the control group, serum folate increased in parallel with increasing supplemental folic acid by 28, 60 and 79% for the groups supplemented with 100, 200 and 300 mg folic acid, respectively, whilst serum vitamin B 12 concentration remained unchanged. The concentration of tHcy decreased significantly and to a similar extent, regardless of the level of supplementation, by 16, 12 and 17% after supplementation with 100, 200 and 300 mg folic acid, respectively. Table 2 also shows that dietary folate intake (excluding folic acid from the fortified breakfast cereals provided) and dietary vitamin B 12 intake, remained unchanged throughout the study period with respect to the control group. Furthermore, when considering total energy intake, percentage of energy derived from protein, fat and carbohydrate, and methionine intake, calculated prior to baseline blood sampling and towards the end of the intervention, values were virtually identical in all four groups. Aggregated data are shown in Table 3 .
Discussion
Our data shows that in free-living individuals the addition of about 100 mg folic acid, given daily as fortified breakfast cereal, is as effective in reducing tHcy concentration as fortification at higher levels. Consumption of breakfast cereals fortified with 100, 200 and 300 mg of folic acid increased serum folate by 28, 60 and 79%, respectively, accompanied by reductions in plasma tHcy of 16, 12 and 17%. Thus we were unable to show a dose -response for tHcy over the range of folic acid fortification used. Two other studies have examined the relationship between folic acid and tHcy involving a level of supplementation starting at around 100 mg. Malinow et al (1998) provided breakfast cereal fortified with multivitamins and minerals including 127, 499 or 665 mg folic acid per portion. Fortification at the two higher doses reduced tHcy whilst fortification at 127 mg did not. Ward et al (1997) provided supplements containing 100, 200 and 400 mg folic acid per day over three consecutive periods. A significant lowering in plasma tHcy was achieved using 100 mg folic acid with a further decline after the 200 mg period; 400 mg produced no additional benefit. The findings of Malinow et al (1998) appear to be in conflict with our own and those of Ward et al (1997) . A possible explanation may lie in the different assays used to measure plasma folate. Malinow et al used the Bio-Rad Quantaphase II (RA) kit which has been reported to produce results lower than those obtained using a microbiological assay (Lactobacillus casei), on the other hand, the method we used (ACS180 1 ) produces serum folate values greater than those obtained using the microbiological method (Gunter et al, 1996) . Thus failure to demonstrate any effect on tHcy using low dose folic acid fortification and lower than expected responses from tHcy using higher levels of fortification (Homocysteine Lowering Trialists' Collaboration, 1998) in the study by Malinow et al (1998) may result from the fact that their subjects had achieved a relatively high level of plasma folate prior to the study. Indeed this is likely given that in the United States fortification of enriched cereal grain products had commenced 2 y prior to the publication of their study (Lawrence et al, 1999) . With reference to the microbiological assay, there appears to be a clear inverse association between tHcy and plasma folate when plasma folate is less than 15 nmol=l and a less robust relationship when plasma folate exceeds this level (Lewis et al, 1992) . While this appears to be the most likely explanation of the differences in response of tHcy between the study by Malinow et al (1998) and our own study, it should also be noted that participants in the Malinow study were older individuals with ischaemic heart disease while those in the Ward et al (1997) study and our own study were younger and free of clinical disease. Indeed, Wald et al (2001) found that patients with ischemic heart disease required daily doses of folic acid of up to 800 mg to optimally lower tHcy.
It is of interest that one of the potentially important clinical and public health benefits of folate, namely its association with tHcy and vascular disease, appears to require a level of serum folate (around 15 nmol=l, Lewis et al, 1992) , which can be achieved with a very small amount of supplemental folic acid. This observation is relevant to national policies regarding fortification. Data from the Framingham Offspring Study (using the microbiological assay) suggests that mandatory fortification in the US was associated with an increase in average plasma folate levels (Jacques et al, 1999) . In non-supplement users the average plasma folate level rose from 10.4 nmol=l pre-fortification to Low-dose fortification with folic acid BJ Venn et al 22.7 nmol=l post-fortification, accompanied by a reduction in average levels of tHcy. An increase in the average plasma folate level in supplement users from 25.8 to 42.9 nmol=l was not associated with a reduction in tHcy, indeed levels rose slightly. These findings suggest that the potential to lower tHcy with folic acid may have been substantially achieved at the current level of fortification in the United States, 140 mg=100 g enriched cereal-grain product. Before mandatory fortification was introduced it was estimated that there would be a rather modest average increase in folic acid intake of around l00 mg per person per day (Department of Health and Human Services, Food and Drug Administration 1993).
Since then it has been demonstrated that fortified foods in the United States contain up to twice as much (and in some foods three times as much), total folate content as that indicated on the label (Rader et al, 2000) . Presumably this action has been taken by manufacturers to ensure adequate levels of folic acid during the shelf life of their products, a practice referred to as 'overage'. Thus, average intake of folic acid is likely to be greater than that estimated initially, a view supported by experimental evidence. The percentage increase in median red blood cell folate levels for young women participating in the US National Health and Nutrition Examination Surveys (NHANES III and NHANES 1999; CDC, 1999) , was similar to the increase observed when young women were supplemented with 400 mg folic acid for 6 months (Firth et al, 1998) . Also, in the three studies that have used folic acid in doses of 100 mg (including our results), the percentage increases in serum folate concentrations have ranged between 18 and 31% (Malinow et al, 1998; Ward et al, 1997) . In comparison, levels of serum folate have more than doubled in non-users of B vitamin supplements in the Framingham and NHANES groups (Jacques et al, 1999; CDC, 1999) . Increases of this magnitude match more closely those observed by Riddell et al (2000) and Ward et al (1997) when subjects consumed 300 -400 mg folic acid for 12 -14 weeks, respectively. Differences in time scales between the experimental investigations and epidemiological observations of the Framingham and NHANES studies do not account for the observed differences since serum folate levels appear to stabilise relatively rapidly when folic acid intakes are increased (Ward et al, 1997) . From biochemical measurements it would seem likely that average intakes of folic acid in the United States as a result of voluntary and mandatory fortification are well above 100 mg. The average folic acid intake of young women, taking into account mandatory fortification but excluding supplements, was found to be 263 mg per day without correction for 'overages' (Firth et al, 1998 ). When considering an optimal level of fortification with folic acid it is of course also necessary to consider the folate status likely to be associated with low risk of NTDs as well as the upper safe limits defined for various age groups (US Institute of Medicine, 1998). Daly et al, (1995) have suggested a dose -response relationship between red blood cell folate and protection against NTDs. When adjusted for methodological differences identified in folate assays (Gunter et al, 1996) , the majority of women studied in the NHANES 1999 survey had red blood cell folate values in the range considered low risk for NTDs (Daly et al, 1995) . Retrospective analyses of two nutrition surveys in the US suggest that recent fortification practices may have resulted in 15 -25% of children aged 1 -8 y exceeding the recommended tolerable upper intake for this age group (Lewis et al, 1999) . Excessive intakes of folic acid are also of concern for those with low cobalamin status, particularly the elderly, who may be at risk for masking of pernicious anaemia and exacerbation of vitamin B 12 deficient neuropathy (Weir et al, 1999) . Estimates regarding the proportion of individuals exceeding recommended upper levels of intake are likely to be conservative since they may not take account of the fact that manufacturers deliver substantially more folic acid into the food supply than the nominal level (Rader et al, 2000) , the increasing use of supplements, an increase in prescriptions, an increase in the number of fortified products, or recent changes in consumer choices of fortified foods given the heightened awareness of folic acid (UK Department of Health, 2000) . Modelling studies using measured levels of fortification rather than amounts stated on the label are needed to provide current estimations of folic acid intakes of young women and other groups at risk of excessive consumption.
In conclusion it appears from the data generated in this study regarding the effects of folic acid on tHcy levels, that fortification can be effective at a relatively low level. Furthermore, epidemiological studies suggest that red blood cell folate concentrations in young American women are approaching levels consistent with low risk for NTDs. Thus, low level fortification may be appropriate for reducing tHcy as well as risk for NTDs, since when aggregated from all sources and correcting for 'overages', total folic acid intake may be greater than initially predicted and sufficient to appreciably improve folate status of the entire population. It seems inappropriate to recommend levels of fortification higher than those used in the United States -be it voluntary or mandatory -without first establishing current estimates of folic acid consumption and monitoring the effect of fortification at lower levels.
